Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
収録刊行物
-
- The Lancet
-
The Lancet 396 (10265), 1817-1828, 2020-12
Elsevier BV